About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Clinicaltrials.gov identifier NCT03929965

Recruitment Status Recruiting

First Posted April 29, 2019

Last update posted April 29, 2019

Study Description

Brief summary:

This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.

  • Condition or Disease:Advanced Solid Tumor
  • Intervention/Treatment: Drug: Anlotinib
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 30 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Anlotinib in Advanced Solid Tumors With FGFR Alteration
  • Estimated Study Start Date: July 2019
  • Estimated Primary Completion Date: July 2020
  • Estimated Study Completion Date: July 2023
Arms and interventions
Arm Intervention/treatment
Experimental: advanced solid tumors with FGFR alteration
Drug: Anlotinib
Anlotinib
Outcome Measures
  • Primary Outcome Measures: 1. Objective Response Rate(ORR) [ Time Frame: up to 36 months ]
    Evaluation of tumor burden based on RECIST criteria.
Eligibility Criteria
  • Ages Eligible for Study: 18 to 75 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

Patients should be histologically diagnosed with advanced solid tumors; Patients with FGFR
mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions;
Patients are not available for targeted therapy or patients refuse to receive targeted
therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy
focus was not be measured; Age should be 18-25 years; Performance status should be 0-2;
Life expectancy should be more than 12 weeks;

Exclusion Criteria:

Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to
experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain
metastases; Patients with chemotherapy contraindication; Patients could not tolerate
chemotherapy; Patients have secondary primary tumor.

Contacts and Locations
Contacts
Locations

China, Shanghai
Shanghai Changzheng Hospital
Shanghai

China, Shanghai
Shanghai Changzheng Hospital
Shanghai

China, Shanghai
Shanghai Changzheng Hospital
Shanghai

Sponsors and Collaborators

Shanghai Changzheng Hospital

More Information
  • Responsible Party: Shanghai Changzheng Hospital
  • ClinicalTrials.gov Identifier: NCT03929965 History of Changes
  • Other Study ID Numbers: ASTFA
  • First Posted: April 29, 2019 Key Record Dates
  • Last Update Posted: April 29, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Shanghai Changzheng Hospital: Anlotinib
    FGFR
    solid tumors
  • Additional relevant MeSH terms: Neoplasms